Multicenter Phase I/II Trial of Ruxolitinib in Combination With Decitabine in Patients With Accelerated Phase Myeloproliferative Neoplasm (MPN) or Post-MPN AML

Trial Profile

Multicenter Phase I/II Trial of Ruxolitinib in Combination With Decitabine in Patients With Accelerated Phase Myeloproliferative Neoplasm (MPN) or Post-MPN AML

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs Ruxolitinib (Primary) ; Decitabine
  • Indications Myeloproliferative disorders
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 23 Mar 2017 Planned End Date changed from 1 Feb 2018 to 1 Feb 2019.
    • 23 Mar 2017 Planned End Date changed from 1 Feb 2018 to 1 Feb 2019.
    • 06 Dec 2016 Results of a Phase I Study (n=21) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top